|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | T0 | T3 | T6 | T9 | T12 |
| Tapering csDMARD |  |  |  |  |  |
| Full dose | 0% | 11% | 7% | 11% | 10% |
| ½ dose | 100% | 8% | 7% | 8% | 15% |
| ¼ dose | 0% | 77% | 31% | 10% | 7% |
| Tapered | 0% | 4% | 55% | 71% | 68% |
|  |  |  |  |  |  |
| Tapering TNF-inhibitor |  |  |  |  |  |
| Full dose | 0% | 4% | 11% | 15% | 18% |
| ½ dose | 100% | 18% | 12% | 10% | 11% |
| ¼ dose | 0% | 78% | 66% | 17% | 20% |
| Tapered | 0% | 0% | 11% | 58% | 51% |
| csDMARD: conventional synthetic disease modifying anti-rheumatic drug | | | | | |

**Supplemental table S2 Detailed overview of percentages of patients in the indicated tapering status per time point**